Biogen reports more data for anti-LINGO mAb in optic neuritis

Biogen Inc. (NASDAQ:BIIB) reported new data from the Phase II RENEW study of BIIB033 to treat acute optic neuritis, showing that patients receiving the compound had "continuous improvement" for 12 weeks after receiving the last dose of the antibody against leucine-rich repeat neuronal protein 1 ( LINGO-1).

New results from the intent-to-treat population showed BIIB033 had a 6.06 msec improvement over placebo at 32 weeks (p=0.07) on the primary endpoint of improvement in recovery of optic nerve conduction latency as measured by full-field visual evoked potential (FF-VEP). At 24 weeks, the improvement vs. placebo was 3.48 msec (p=0.33). The last dose of BIIB033 was given at week 20. ...